Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma

BackgroundAs an emerging therapy with a promising efficacy, immunotherapy has been widely used in the treatment of solid tumors and hematologic malignancies. This clinical study compares the efficacy of tislelizumab, a domestic immune checkpoint inhibitor (ICI), to that of sorafenib when used as a f...

Full description

Bibliographic Details
Main Authors: Qijun Li, Yong Dong, Yubin Pan, Honglin Tang, Da Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Immunology
Subjects:
immune checkpoint inhibitors
double primary tumors
hepatocellular carcinoma
B-cell indolent lymphoma
tislelizumab
misdiagnosis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.634559/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.634559/full

Similar Items